Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment in its Phase III SANOVO study in China. The study evaluates the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) for the first-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations and MET overexpression. The final patient was enrolled on August 18, 2025.
Study Details
The Phase III SANOVO study focuses on the combination of Orpathys and Tagrisso. Orpathys, a potent and highly selective oral MET TKI, addresses MET receptor tyrosine kinase signaling pathway abnormalities. Tagrisso, a third-generation EGFR-TKI, has shown clinical activity in treating NSCLC patients, including those with central nervous system metastases.
Treatment Strategy
This combination therapy offers a promising chemotherapy-free, oral treatment strategy. It aims to address drug resistance mechanisms in advanced lung cancer, providing a new treatment option for patients with specific NSCLC profiles.-Fineline Info & Tech
